Suppr超能文献

相似文献

1
Identification of Prodromal Parkinson Disease: We May Be Able to But Should We?
Neurology. 2024 Jun 11;102(11):e209394. doi: 10.1212/WNL.0000000000209394. Epub 2024 May 17.
3
Risk disclosure in prodromal Parkinson's disease - A survey of neurologists.
Parkinsonism Relat Disord. 2023 Jan;106:105240. doi: 10.1016/j.parkreldis.2022.105240. Epub 2022 Dec 8.
4
Prodromal Parkinson's disease: hype or hope for disease-modification trials?
Transl Neurodegener. 2022 Feb 21;11(1):11. doi: 10.1186/s40035-022-00286-1.
5
Risk Disclosure in Prodromal Parkinson's Disease.
Mov Disord. 2021 Dec;36(12):2833-2839. doi: 10.1002/mds.28723. Epub 2021 Aug 5.
6
Who to Enroll in Parkinson Disease Prevention Trials? The Case for Composite Prodromal Cohorts.
Neurology. 2022 Aug 16;99(7 Suppl 1):26-33. doi: 10.1212/WNL.0000000000200788.
7
Patients' views on the ethical challenges of early Parkinson disease detection.
Neurology. 2020 May 12;94(19):e2037-e2044. doi: 10.1212/WNL.0000000000009400. Epub 2020 Apr 14.
8
The prodromes of Parkinson's disease.
Eur J Neurosci. 2019 Feb;49(3):320-327. doi: 10.1111/ejn.14269. Epub 2018 Dec 5.
9
Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease.
JAMA Neurol. 2023 Feb 1;80(2):161-171. doi: 10.1001/jamaneurol.2022.3902.
10
Biomarkers in Prodromal Parkinson Disease: a Qualitative Review.
J Int Neuropsychol Soc. 2016 Nov;22(10):956-967. doi: 10.1017/S1355617716000503.

引用本文的文献

1
High-risk populations should be screened for MS: Yes.
Mult Scler. 2025 Aug;31(9):1032-1034. doi: 10.1177/13524585251353044. Epub 2025 Jul 8.
2
Phenotyping Healthcare Use 2-3 Decades Before the First Multiple Sclerosis Demyelinating Event.
Ann Clin Transl Neurol. 2025 Aug;12(8):1585-1594. doi: 10.1002/acn3.70092. Epub 2025 Jun 12.
3
The prodromal individuals' perspective on active recruitment for early detection of α-synucleinopathies.
NPJ Parkinsons Dis. 2025 May 9;11(1):121. doi: 10.1038/s41531-025-00979-0.
4
Healthcare use is elevated two decades before a first demyelinating event and differs by age and sex.
Ann Clin Transl Neurol. 2025 Feb;12(2):415-432. doi: 10.1002/acn3.52267. Epub 2025 Jan 29.
5
The Ethical Landscape of Prodromal Parkinson Disease: Considerations for Shared Decision-Making and Health Equity.
Neurology. 2024 Jun 11;102(11):e209522. doi: 10.1212/WNL.0000000000209522. Epub 2024 May 17.

本文引用的文献

1
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease.
Mov Disord. 2023 Sep;38(9):1636-1644. doi: 10.1002/mds.29496. Epub 2023 Jun 15.
2
Propagative α-synuclein seeds as serum biomarkers for synucleinopathies.
Nat Med. 2023 Jun;29(6):1448-1455. doi: 10.1038/s41591-023-02358-9. Epub 2023 May 29.
3
The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure.
Mov Disord. 2023 Jun;38(6):1089-1093. doi: 10.1002/mds.29403. Epub 2023 Apr 12.
4
Racial and Ethnic Differences in Health-Related Quality of Life for Individuals With Parkinson Disease Across Centers of Excellence.
Neurology. 2023 May 23;100(21):e2170-e2181. doi: 10.1212/WNL.0000000000207247. Epub 2023 Apr 5.
5
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward.
Neurology. 2022 Aug 2;99(5):195-205. doi: 10.1212/WNL.0000000000200878. Epub 2022 Jun 3.
6
Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study.
Parkinsonism Relat Disord. 2022 May;98:72-74. doi: 10.1016/j.parkreldis.2022.04.001. Epub 2022 Apr 19.
7
The Disease Modification Conundrum in Parkinson's Disease: Failures and Hopes.
Front Aging Neurosci. 2022 Feb 28;14:810860. doi: 10.3389/fnagi.2022.810860. eCollection 2022.
8
Risk Disclosure in Prodromal Parkinson's Disease.
Mov Disord. 2021 Dec;36(12):2833-2839. doi: 10.1002/mds.28723. Epub 2021 Aug 5.
9
How Do Patients With Parkinson's Disease Approach Advance Care Planning? A UK-Based Mixed Methods Study.
J Geriatr Psychiatry Neurol. 2022 Jan;35(1):168-175. doi: 10.1177/0891988720988917. Epub 2021 Jan 19.
10
Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population.
Mov Disord. 2021 Jan;36(1):133-142. doi: 10.1002/mds.28265. Epub 2020 Oct 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验